Company intelligence / Profile preview
AgonOx, Inc.
Portland, Oregon, United Statesagonox.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
First patient dosed in August 2023 in a Phase 1 clinical trial evaluating AGX148 alone and in combination with Phio's PH-762 in patients with melanoma and other advanced solid tumors. The trial is assessing safety and therapeutic potential of AgonOx's AGX148 "double positive" (DP) CD8 tumor-infiltrating lymphocytes.
- Therapeutic areas
- Oncology
- Modalities
- TIL therapyBiological productsAntibody-Coupled T Cell Receptor TherapyTCR therapyFusion protein
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Phio Pharmaceuticals Corp.Providence Cancer Institute of Oregon
Beyond the preview
Go deeper on AgonOx, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AgonOx, Inc..